Regen BioPharma pursues joint ventures for AI-based clinical trial research
RGBP•Regen BioPharma is pursuing joint ventures for research programs using artificial intelligence modeling for clinical trials, and expects a nonbinding letter of intent to be signed shortly.
1. Joint venture plans
Regen BioPharma is pursuing joint ventures for research programs using artificial intelligence modeling for clinical trials. A nonbinding letter of intent is expected to be signed shortly.
